HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Haderslev, K. V Articles by Staun, M. Search for Related Content PubMed PubMed Citation Articles by Haderslev, K. V Articles by Staun, M. Agricola Articles by Haderslev, K. V Articles by Staun, M.

Effect of cyclical intravenous clodronate therapy on bone mineral density and markers of bone turnover in patients receiving home parenteral nutrition^1,2,3

¹ From the Department of Gastroenterology, Copenhagen University Hospital, Rigshospitalet, Copenhagen (KVH, LT, and MS), and the Department of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark (HAS).

Background: Patients receiving home parenteral nutrition (HPN) because of intestinal failure are at high risk of developing osteoporosis.

Objective: We studied the effect of the bisphosphonate clodronate on bone mineral density (BMD) and markers of bone turnover in HPN patients.

Design: A 12-mo, double-blind, randomized, placebo-controlled trial was conducted to study the effect of 1500 mg clodronate, given intravenously every 3 mo for 1 y, in 20 HPN patients with a bone mass T score of the hip or lumbar spine of less than -1. The main outcome measure was the difference in the mean percentage change in the BMD of the lumbar spine measured by dual-energy X-ray absorptiometry. Secondary outcome measures included changes in the BMD of the hip, forearm, and total body and biochemical markers of bone turnover, ie, serum osteocalcin, urinary pyridinoline, and urinary deoxypyridinoline.

Results: The mean (±SEM) BMD of the lumbar spine increased by 0.8 ± 2.0% in the clodronate group and decreased by 1.6 ± 2.0% in the placebo group (P = 0.43). At all secondary skeletal sites (ie, hip, total body, and distal forearm), we observed no changes or small increases in the BMD of the clodronate group and decreases in the BMD of the placebo group. In the clodronate group, biochemical markers of bone resorption decreased significantly (P < 0.05).

Conclusions: Clodronate significantly inhibits bone resorption as assessed by changes in biochemical markers of bone turnover. Although the mean BMD increased in the clodronate group, cyclic clodronate therapy failed to increase spinal BMD significantly at 12 mo.

Key Words: Clodronate • home parenteral nutrition • bone resorption • osteoporosis • bone mass • bone turnover • bone mineral density

This article has been cited by other articles:

				M. Ferrone and M. Geraci A Review of the Relationship Between Parenteral Nutrition and Metabolic Bone Disease Nutr Clin Pract, June 1, 2007; 22(3): 329 - 339. [Abstract] [Full Text] [PDF]

				M. Raman, E. Aghdassi, M. Baun, M. Yeung, L. Fairholm, O. Saqui, and J. P. Allard Metabolic Bone Disease in Patients Receiving Home Parenteral Nutrition: A Canadian Study and Review JPEN J Parenter Enteral Nutr, November 1, 2006; 30(6): 492 - 496. [Abstract] [Full Text] [PDF]